Incidence and resolution of eribulin-induced peripheral neuropathy (IRENE) in patients with locally advanced or metastatic breast cancer

被引：0
|
作者：
Schmidt, M. [1 ]
Jackisch, C. [2 ]
Hesse, T. [3 ]
Hoffmann, O. [4 ]
Heinrich, B. J. [5 ]
Park-Simon, T-W [6 ]
Grischke, E-M. [7 ]
Weide, R. [8 ]
Mueller-Huesmann, H. [9 ]
Welslau, M. [10 ]
Wu, J. [11 ]
Schmitz, H. [12 ]
Engelbrecht, C. [13 ]
Lueck, H-J. [14 ]
机构：
[1] Univ Klinkum Mainz, Dept Gynecol, Mainz, Germany
[2] Sana Klinikum Offenbach GmbH, Dept Obstet & Gynecol, Offenbach, Germany
[3] Agaples Diakonieklinikum Rotenburg gGmbH, Dept Gynecol, Rotenburg, Germany
[4] Univ Klinikum Essen, Dept Gynecol & Obstet, Essen, Germany
[5] Praxis Heinrich Bangerter, Hematol Oncol, Augsburg, Germany
[6] MHH Hannover, Dept Gynecol, Hannover, Germany
[7] Univ Frauenklin Tubingen, Oncol, Tubingen, Germany
[8] Praxis Hamatol & Onkol Koblenz, Oncol Outpatient Dept, Koblenz, Germany
[9] Bruderkrankenhaus St Josef Paderborn, Dept Hematol Oncol, Paderborn, Germany
[10] Klinikum Aschaffenburg, Hematol Oncol, Aschaffenburg, Germany
[11] Eisai Inc, Biostat, Woodcliff Lake, NJ USA
[12] Eisai GmbH, Dept Med, Frankfurt, Germany
[13] Eisai GmbH, Med Affairs, Frankfurt, Germany
[14] Gynakol Onkol Praxis Pelikanpl, Gynecol Oncol, Hannover, Germany
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.587
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
304P
引用
收藏
页码：S496 / S497
页数：2
相关论文
共 50 条
  • [11] Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study
    Takayuki Kobayashi
    Jyunichi Tomomatsu
    Ippei Fukada
    Tomoko Shibayama
    Natsuki Teruya
    Yoshinori Ito
    Takuji Iwase
    Shinji Ohno
    Shunji Takahashi
    BMC Cancer, 16
  • [12] Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer
    Goto, Wataru
    Kashiwagi, Shinichiro
    Asano, Yuka
    Takada, Koji
    Morisaki, Tamami
    Fujita, Hisakazu
    Takashima, Tsutomu
    Ohsawa, Masahiko
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2018, 38 (05) : 2929 - 2938
  • [13] Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
    Vahdat, Linda T.
    Garcia, Agustin A.
    Vogel, Charles
    Pellegrino, Christine
    Lindquist, Deborah L.
    Iannotti, Nicholas
    Gopalakrishna, Prashanth
    Sparano, Joseph A.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (02) : 341 - 351
  • [14] Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
    Linda T. Vahdat
    Agustin A. Garcia
    Charles Vogel
    Christine Pellegrino
    Deborah L. Lindquist
    Nicholas Iannotti
    Prashanth Gopalakrishna
    Joseph A. Sparano
    Breast Cancer Research and Treatment, 2013, 140 : 341 - 351
  • [15] Risk Factors for Eribulin-induced Severe Neutropenia in Patients With Recurrent Breast Cancer
    Takada, Shinya
    Hosokawa, Yoshihiro
    Umehara, Kengo
    Kimura, Yuta
    Fukai, Yuta
    Shikishima, Karin
    Yamamoto, Mitsugu
    Maeda, Hideki
    Tomioka, Nobumoto
    Watanabe, Kenichi
    Hashishita, Hirokazu
    IN VIVO, 2024, 38 (01): : 500 - 505
  • [16] Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC)
    Jansen, M.
    Vernaz-Gris, M.
    DesJardins, C.
    Wong, N.
    Campone, M.
    Cortes, J.
    Wanders, J.
    Shuster, D.
    Fuseau, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [17] Comparison of the Incidence of Peripheral Neuropathy with Eribulin Mesylate Versus Ixabepilone in Metastatic Breast Cancer Patients: A Randomized Phase II Study.
    Vandat, L.
    Gopalakrishna, P.
    Garcia, A. A.
    Vogel, C.
    Pellegrino, C.
    Lindquist, D.
    Iannotti, N.
    CANCER RESEARCH, 2011, 71
  • [18] Safety and efficacy of eribulin in patients with locally advanced or metastatic breast cancer: A phase IV study in India
    Choudhary, Vaibhav
    Satheesh, C. T.
    Bose, Chinmoy K.
    Rajan, Shiv
    Prakash, Ss
    Desai, Chirag
    Lin, Xiao
    Patil, Balaji
    Chaudhari, Sameer
    Gupta, Sudeep
    ANNALS OF ONCOLOGY, 2022, 33 : S537 - S537
  • [19] Eribulin mesylate in patients with locally advanced unresectable or metastatic breast cancer: results and implications of the clinical trials
    Ramnaraign, Brian
    Page, David
    Fornier, Monica
    BREAST CANCER MANAGEMENT, 2015, 4 (03) : 135 - 144
  • [20] Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer
    Cortes, Javier
    Lorca, Rebeca
    FUTURE ONCOLOGY, 2011, 7 (03) : 355 - 364
12345